The recent inhibitor, AZD3470, which inhibits PRMT5 activity by binding to the PRMT in the presence of methylthioadenosine (MTA), in methylthioadenosine phosphorylase (MTAP)-deficient tumor cells (Spira et al., 2024), has recently been developed by AstraZeneca and is currently being tested in two different clinical trials (NCT06137144 - ClinicalTrials.gov, 2024p and NCT06130553 - ClinicalTrials.gov, 2024g). The gene discussed is MTAP; the disease is neoplasm.